Conclusion
The world"s largest study for Atrial Fibrillation, The SAFER-study, has been expanded to carry out and evaluate how distance screening can be done without any physical meeting needed, The first COVID-19 secured patient in Great Britain have now been screened. While not estimate or stock moving per se, we see this as proof of fast and agile adoption to current market conditions as well as downside protection on sales estimates if additional lockdowns would occur, due to the possibility to continue the arrhythmia investigations in distance



The facts
The SAFER-study is the world’s largest screening for Atrial Filibration and covers a total of 120 000 patients aged over 65 in 300 general practises within NHS across England and is financed by National Institute for Health Research. The study is led by researchers from Cambridge University since 2018.

The patients will be loaned a handheld ECG device, provided by Zenicor, to measure ECG twice a day at home for two weeks. Patients in 100 practises will undergo the screening and the other 200 will not. Both set of patients will be followed up during five years, whether the screenings and treatments leads to fewer strokes, heart attacks and deaths. Patients who are found to have atrial fibrillation by the screening within this study will be offered treatment with anticoagulant drugs.

Länk till analysen